Assessment of patterns of care in maintenance therapy for stage 3 Non-Small Cell Lung Cancer in US patients undergoing definitive chemoradiation
Latest Information Update: 28 Feb 2022
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Feb 2022 New trial record
- 01 Feb 2022 Results published in the American Journal of Clinical Oncology